基于"态靶辨证"理论探讨药对治疗溃疡性结肠炎研究进展OA
Research Progress on Drug Pairs for Treating Ulcerative Colitis Based on the Theory of"State-Target Syndrome Differentiation"
溃疡性结肠炎(ulcerative colitis,UC)的主要症状为腹泻、便血、腹痛,可作为"症靶".在态靶辨证理论下,使用症靶药物应尽量符合分态,药对打靶时也应遵循该原则,方可发挥中医因人施治的优势.具体则言,针对UC的三大"症靶",已有相应药对展现出独特疗效;补骨脂-肉豆蔻药对通过温肾暖脾、固肠止泻,对UC腹泻具有专一性疗效;三七-白及药对通过止血不留瘀、敛疮护肠络,对UC便血展现出良好潜力;延胡索-白芷药对通过通络止痛,对UC腹痛具有应用价值.当前,关于药对治疗UC的研究存在以下问题:(1)在"症靶"层面,UC作为西医病名,与中医以"虚劳"等症状命名的疾病体系存在差异,这些中医症状能否作为UC精准治疗的"症靶",其科学内涵与对应关系亟待阐明;(2)在研究内容上,现有文献多聚焦于药对的分子机制,而对其协同增效的临床验证,以及对特定症状的疗效评估则相对薄弱.未来,UC药对的研究应转向更高层次的临床与转化应用,一方面,需通过高质量的临床试验及动物研究,深入探索UC药对的协同增效规律及其"症靶"潜力;另一方面,应重视中医适宜技术带来的新机遇,灌肠、栓剂等直肠给药途径,不仅能显著提高部分药物的生物利用度,也为药对研究开辟了新路径.
The main symptoms of ulcerative colitis(UC),such as diarrhea,bloody stools,and abdominal pain,can be regarded as"symptom targets."Under the theory of state-target syndrome differentiation,the selection of drugs for these symptom targets should ad-here as closely as possible to the principle of state classification.Similarly,when applying drug pairs to hit these targets,this principle should be followed to leverage the strength of TCM in providing individualized treatment.Specifically,for the three major"symptom tar-gets"of UC,corresponding drug pairs have demonstrated unique therapeutic effects:Buguzhi(Fructus Psoraleae)-Roudoukou(Semen Myristicae)pair exhibits specific efficacy against UC-related diarrhea by warming the kidney and spleen,and consolidating the intestines to stop diarrhea.Sanqi(Radix et Rhizoma Notoginseng)-Baiji(Rhizoma Bletillae)pair shows promising potential for UC-related bloody stools by stopping bleeding without causing blood stasis,and promoting wound healing while protecting the intestinal collaterals.Yan-husuo(Rhizoma Corydalis)-Baizhi(Radix Angelicae Dahuricae)pair has application value for UC-related abdominal pain by unblock-ing collaterals to relieve pain.Currently,research on drug pairs for treating UC faces the following problems:(1)At the"symptom tar-get"level,UC is a Western medical disease name,differing from the TCM disease-naming system based on symptoms like"consumptive disease."Whether these TCM symptoms can serve as precise"symptom targets"for UC treatment,along with their scientific connota-tion and corresponding relationships,urgently needs clarifying.(2)Regarding research content,existing literature predominantly focuses on the molecular mechanisms of drug pairs,while clinical validation of their synergistic effects and efficacy evaluation for specific symp-toms remain relatively weak.Therefore,future research should shift toward higher-level clinical and transformation applications.On the one hand,high-quality clinical and animal studies are needed to deeply explore the synergistic rules and"symptom target"potential of drug pairs for UC.On the other hand,attention should be paid to new opportunities brought by appropriate TCM techniques.Rectal ad-ministration routes such as enemas and suppositories,etc.not only significantly enhance the biological availability of certain drugs,but also open new avenues for drug pair research.
QIAN Li;FAN Wenbin;DOU Yuanqun;HUANG Yi
College of Traditional Chinese Medicine,Chongqing Medical University,Chongqing,China,400016Chongqing University of Chinese Medicine,Chongqing,China,402760College of Traditional Chinese Medicine,Chongqing Medical University,Chongqing,China,400016College of Traditional Chinese Medicine,Chongqing Medical University,Chongqing,China,400016
医药卫生
溃疡性结肠炎"态靶辨证""症靶"药对补骨脂-肉豆蔻三七-白及延胡索-白芷
《河南中医》 2026 (1)
21-28,8
重庆市璧山区科技局2024年社会民生领域科学计划项目(BSKJ2024080)
评论